CRL vs SHC
CRL: Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development. SHC: A global provider of essential sterilization and lab testing services for the healthcare industry.
Side-by-side fundamentals
| Metric | CRL | SHC | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $295.19 | $19.57 | |
| Market cap as of 2026-08-24 | $14.1B | $5.6B | |
| P/E as of 2026-08-24 | n/a | 46.08 | |
| PEG as of 2026-08-24 | -0.23 | 4.31 | CRL lower |
| Net margin as of 2026-08-24 | -6.0% | +9.9% | SHC higher |
| Gross margin as of 2026-08-24 | +34.6% | +55.3% | SHC higher |
| Operating margin as of 2026-08-24 | +2.3% | +29.0% | SHC higher |
| ROE as of 2026-08-24 | -7.7% | +20.6% | SHC higher |
| ROA as of 2026-08-24 | -3.2% | +3.6% | SHC higher |
| Debt / equity as of 2026-08-24 | 0.93 | 3.59 | CRL lower |
| Revenue growth (YoY) as of 2026-08-24 | -0.7% | +7.4% | SHC higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | +5.1% | SHC higher |
| Beta as of 2026-08-24 | 1.41 | 1.86 | |
| 1-year return as of 2026-08-21 close | +91.0% | +22.8% | CRL higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.